Issue 26, 2013

Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug

Abstract

Chemi-enzymatic synthesis of ribavirin acrylate and subsequent RAFT co-polymerization with acrylic acid afforded a formulation of a broad spectrum antiviral drug which avoids accumulation in erythrocytes, the origin of the main side effect of ribavirin. In cultured macrophages the macromolecular prodrugs exhibited decreased toxicity while maintaining the anti-inflammatory action of ribavirin.

Graphical abstract: Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug

Supplementary files

Article information

Article type
Communication
Submitted
14 Jan 2013
Accepted
07 Feb 2013
First published
08 Feb 2013

Chem. Commun., 2013,49, 2643-2645

Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug

M. B. L. Kryger, B. M. Wohl, A. A. A. Smith and A. N. Zelikin, Chem. Commun., 2013, 49, 2643 DOI: 10.1039/C3CC00315A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements